Diabetes Metab J.  2022 Jan;46(1):162-163. 10.4093/dmj.2021.0331.

Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study (Diabetes Metab J 2021;45:675-83)

Affiliations
  • 1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
  • 2Department of Internal Medicine, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Korea
  • 3Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
  • 4Department of Internal Medicine, Division of Endocrinology and Metabolism, Research Institute of Clinical Medicine of Jeonbuk National UniversityBiomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea


Reference

1. Moon JS, Suh S, Kim SS, Jin HY, Kim JM, Jang MH, et al. Efficacy and safety of treatment with quadruple oral hypoglycemic agents in uncontrolled type 2 diabetes mellitus: a multi-center, retrospective, observational study. Diabetes Metab J. 2021; 45:675–83.
2. Cho YK, Lee J, Kim HS, Park JY, Jung CH, Lee WJ. Clinical efficacy of quadruple oral therapy for type 2 diabetes in real-world practice: a retrospective observational study. Diabetes Ther. 2020; 11:2029–39.
Article
3. Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study. Diabetes Res Clin Pract. 2019; 151:65–73.
Article
4. Ku EJ, Lee DH, Jeon HJ, Oh TK. Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice. Diabetes Obes Metab. 2019; 21:173–7.
Article
5. Jeon HJ, Ku EJ, Oh TK. Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control. Diabetes Res Clin Pract. 2018; 142:188–94.
Article
6. Fu AZ, Sheehan JJ. Treatment intensification for patients with type 2 diabetes and poor glycaemic control. Diabetes Obes Metab. 2016; 18:892–8.
Article
7. Kim SG, Kim NH, Ku BJ, Shon HS, Kim DM, Park TS, et al. Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): a prospective observational DIPP-FACTOR study in Korea. J Diabetes Investig. 2017; 8:346–53.
Article
Full Text Links
  • DMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr